These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Editorial comment on: Prostate-specific antigen improves the ability of clinical stage and biopsy gleason sum to predict the pathologic stage at radical prostatectomy in the new millennium. Stenman UH Eur Urol; 2007 Oct; 52(4):1074-5. PubMed ID: 17383813 [No Abstract] [Full Text] [Related]
14. Editorial comment on: systematic assessment of the ability of the number and percentage of positive biopsy cores to predict pathologic stage and biochemical recurrence after radical prostatectomy. Greene DR Eur Urol; 2007 Sep; 52(3):744-5. PubMed ID: 17350749 [No Abstract] [Full Text] [Related]
15. Editorial comment on: systematic assessment of the ability of the number and percentage of positive biopsy cores to predict pathologic stage and biochemical recurrence after radical prostatectomy. Trpkov K Eur Urol; 2007 Sep; 52(3):743-4. PubMed ID: 17350751 [No Abstract] [Full Text] [Related]
19. Pretreatment prostate-specific antigen velocity and the risk of death from prostate cancer in the individual with low-risk prostate cancer. D'Amico AV; Chen MH J Clin Oncol; 2009 Aug; 27(22):3575-6. PubMed ID: 19506151 [No Abstract] [Full Text] [Related]
20. Can preoperative PSA doubling time and PSA velocity predict outcomes following radical prostatectomy? Grubb RL; Andriole GL Nat Clin Pract Urol; 2006 Jun; 3(6):306-7. PubMed ID: 16763640 [No Abstract] [Full Text] [Related] [Next] [New Search]